BioInvent International has announced the appointment of Sylvie Ryckebusch as Chief Business Officer (CBO).
“Sylvie Ryckebusch has already made an important contribution to the development of BioInvent’s business, including the licensing deal with CASI Pharmaceuticals in 2020, the restructuring of a clinical development agreement with Cancer Research UK in 2021, and a supply and clinical collaboration agreement with MSD/Merck on BI-1808 in 2021. I look forward to working more closely with Sylvie as we continue to progress our exciting pipeline of immuno-modulatory antibodies for cancer through clinical development and towards market, with several potential partnering opportunities along the way,” says Martin Welschof, CEO of BioInvent.
Sylvie Ryckebusch is a pharmaceutical executive with over 20 years of experience in business development, alliance management, and corporate strategy. She has held senior leadership roles in both large multi-national corporations and biotech companies and has closed numerous biotech deals at all stages of a product life cycle. She has supported BioInvent on a part time basis since 2019 and with the new position as CBO, she will join the company’s executive management team.
Prior to joining BioInvent, Sylvie has served in key positions at Serono, Merck KGaA, and Index Ventures as well as McKinsey and Company and the Harvard Business School. Sylvie holds a PhD in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland.
Photo of Sylvie Ryckebusch: Nille Leander